Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November
Lexeo Therapeutics, Inc. LXEO
$3.04
▼ -3.18%
($-0.10)
🔥 High Short Interest
Open
$3.07
Prev Close
$3.14
Day Range
$2.94 – $3.19
52W Range
$2.55 – $10.99
Market Cap
$257.76M
Beta
1.62
EPS (TTM)
$-1.16
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2023-11-03 |
| Shares Out. | 82,090,000 |
| Website | lexeotx.com ↗ |
| Phone | 12125479879 |
| Employees | 59 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$25.9M |
| Free Cash Flow | -$88.7M |
| Total Assets | $254.9M |
| Total Liabilities | $19.8M |
| Equity | $235.1M |
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Lexeo Therapeutics, Inc. is a publicly traded company under the ticker symbol LXEO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-11-01)